AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00552487 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: synacthen
Description: 1 µg synacthen in the vein
Study NCT05012891 — intervention group
Intervention type: OTHER
Intervention: OneStep Smartphone Application
Description: OneStep technology is a smartphone application (app) utilizing smartphone sensors to provide ongoing gait diagnostics. The eligible study participants will be asked to download and install the app on their own smartphones and carry the smartphone in their front pants pocket at all times.~The app will collect the required gait parameters but, will not present them (or any summary thereof) to the study participants or their physiotherapists, in order not to influence the rehabilitation plan.
Study NCT03466801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone was taken for oral administration with dosage of 1mg/kg/d (maximum 60mg/d) by 8 weeks to start.Then reduced Gradually until the end of the experiment.
Study NCT03466801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MP and CTX
Description: Methylprednisolone(MP) was injected for 3 day(if weight >60kg ,500mg/d\<60kg,300mg/d ), methylprednisolone was 0.4mg/kg/d for 27 day.Cyclophosphamide(CTX) orally was 100mg/ d for 1 month.And repeated for six months.
Study NCT04633551 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory supplement
Description: commercially available combination of curcumin, quercitin, resveratrol, and green tea
Study NCT04018599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg MSB11022
Description: Single dose, as a solution, administered subcutaneously, using an auto-injector.
Study NCT04018599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg MSB11022
Description: Single dose, as a solution, administered subcutaneously, using a pre-filled syringe.
Study NCT01822236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Craniosacral Therapy Program
Description: The ten techniques of craniosacral therapy program are: Still Point (CV-4, Sacred Feet), diaphragms(pelvic, respiratory, thoracic inlet, hyoid, Occipital Cranial Base), Decompression L5-S1, Dural Tube Glide, Lift Front, Parietal Lift, Compression / decompression of the joint sphenobasilar, Temporary Technique, Compression / decompression of the temporomandibular joints, and Still Point CV-4.
Study NCT01822236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One technique of craniosacral therapy
Description: Decompression L5-S1: lumbosacral decompression
Study NCT03243877 — intervention group
Intervention type: OTHER
Intervention: MammoAlert Screening Test
Description: Plasma obtained from blood samples will be analyzed with the MammoAlert Screening Test for the presence of known breast cancer bio-markers.
Study NCT02388867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene (PTFE) bypass grafting.
Description: Polytetrafluoroethylene (PTFE) bypass grafting. Patients will undergo bypass procedure using PTFE graft : the inflow vessel may be the femoral artery or the iliac artery; the outflow vessel may be the popliteal artery or the anterior tibial artery.
Study NCT02388867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autogenous vein bypass grafting
Description: Autogenous vein bypass grafting. Patients will undergo Bypass procedure using autogenous veins (the great saphenous vein or the small saphenous vein or a composite bypass using great and small saphenous vein ). The inflow vessel may be represented by the femoral artery or the popliteal artery; the outflow vessel may be the anterior tibial artery or the posterior tibial artery or the peroneal artery.
Study NCT02870335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: The patient remained lying on the gurney and the treatment was performed in the order set forth below and included: overall bilateral manipulation of L5-S1-Sacroiliac, subsequently decompression hip joint, the tibiofemoral decompression, stretching rotators hip flexion or hip and knee mobilization technique downing head and base of the fibula, tibiofibular-talus tali posteriorización decompression and with the help of a wedge to facilitate technical.
Study NCT02870335 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proprioceptive neuromuscular facilitation
Description: Stretching were conducted in the hamstrings, psoas, adductors, pyramidal, quadriceps and right above.
Study NCT03948555 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI) using ultrasmall super paramagnetic iron oxides (USPIOs)
Description: All patients will undergo two MRI scans (one MRI scan pre-USPIO administration, and one MRI scan 24-36 hours following USPIO administration) and blood samples will be taken for future biomarker analysis.
Study NCT03087019 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Standard use of radiation is administered
Study NCT03087019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is designed to restore the natural ability of the immune system to recognize and target cancer cells.
Study NCT01724853 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: Resection suspension interposition arthroplasty or Arthrodesis
Study NCT01724853 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conservative
Description: Injection
Study NCT01666457 — intervention group
Intervention type: OTHER
Intervention: SOFFI
Description: NICU nursing and multidisciplinary staff were trained to use the SOFFI infant driven feeding program. A small group of learners (20) were trained as resources via a 2-day course and the entire nursing staff received training during a 1-1.5 hour training lecture during their annual competencies.
Study NCT01209143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Vismodegib was supplied in hard gelatin capsules.
Study NCT01209143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Rosiglitazone was supplied in tablets.
Study NCT01209143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone/ethinyl estradiol
Description: Norethindrone/ethinyl estradiol was supplied in tablets.
Study NCT03536260 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant with NanoBone graft
Description: Using of NanoBone graft to fill the gap in the socket after immediate implant placement
Study NCT03536260 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant with Xenograft
Description: Using of Xenograft to fill the gap in the socket after immediate implant placement
Study NCT02647567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine Intake
Description: The experimental group ingest 500 mg of caffeine before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
Study NCT02647567 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Intake
Description: The control group ingest 500 mg of placebo before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
Study NCT03829293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygenation group
Description: usual care + High-flow nasal oxygenation (HFNO) therapy during GI endoscopy under sedation (with a flow at 70L/min and FiO2 50%) through a dedicated system, the THRIVETM (Fisher\&Paykel, New-Zealand)
Study NCT00723021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04191834
Description: 30mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets.
Study NCT00723021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04191834
Description: 100mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets, single dose.
Study NCT00723021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04191834
Description: 2000mg PF-04191834, single dose, oral dispersion + 2 x placebo tables, single dose
Study NCT00723021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zileuton
Description: 1200mg, 2 x 600mg tablets, single dose + placebo oral dispersion, single dose.
Study NCT00723021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x placebo tablets + placebo oral dispersion, single dose.
Study NCT00398645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X 200mcg,GW685698X 200mcg and 400mcg
Study NCT03068065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: the dosage of liraglutide was 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week to the conclusion of the study
Study NCT03068065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: the dosage of metformin was 250 mg thrice a day during the first week, 500 mg thrice a day during the second week, and 1000 mg twice a day from the third week to the conclusion of the study
Study NCT03068065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide
Description: the initial dosage of gliclazide was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/day to achieve a fasting capillary plasma glucose of \<7.0 mmol/L
Study NCT03041519 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fluoroscopy ablation
Description: Catheter ablation will be performed under the guidance of fluoroscopy pllus Ensite NavX.
Study NCT00425802 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: anti-thymocyte globulin
Study NCT05635981 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clearfil Majesty ES-2 Resin Composit Application to Non-carious Cervical Lesions
Description: A restorative treatment method that is applied to non-carious cervical lesions using composite resin restoration after adhesive material application.
Study NCT05635981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clearfil Majesty ES-2 Resin Composit Application to Non-carious Cervical Lesions
Description: A restorative treatment method that is applied to non-carious cervical lesions using composite resin restoration after adhesive material application.
Study NCT01827293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Promethazine
Study NCT01827293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Study NCT03796260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib Test Formulation (F1)
Description: Participants will receive a single oral dose of entrectinib F1 after completion of a standardized meal.
Study NCT03796260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib Reference Formulation (F06)
Description: Participants will receive a single oral dose of entrectinib F06 after completion of a standardized meal.
Study NCT02667977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9 Normal Saline
Description: Use of 0.9 Normal Saline for maintenance IV fluids
Study NCT02667977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.45 Normal Saline
Description: Use of 0.45 Normal Saline for maintenance IV fluids
Study NCT00320125 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Orange juice plus calcium
Description: > 1,200mg Ca (four glasses of orange juice plus calcium)per day
Study NCT00320125 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy products
Description: > 1,200mg Ca (by consuming milk, yogurt, and cheese)
Study NCT02764216 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Elective mucosal irradiaton
Description: Patients will elective mucosal irradiaton based on nodal station, EBV/HPV status, RPN status etc. IMRT will be adopted.
Study NCT05341596 — intervention group
Intervention type: PROCEDURE
Intervention: repeat endotracheal intubation
Description: repeat endotracheal intubation in the PACU after planned extubation of the initial endotracheal intubation for general anesthesia or combined general anesthesia other than that performed in the operating room
Study NCT02091453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APT training
Description: APT training was used as intensive area-specific cognitive training at four levels: sustained, selective, divided and alternating attention. The APT also includes education in acquired attention deficits and training for generalization. Each session took 45-90 minutes to perform. The APT-test was used to determine the level of difficulty for the attention training.
Study NCT02091453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiprofessional rehabilitation
Description: Attention training in activities included standard occupational training within an interdisciplinary rehabilitation programme. The programme consisted of training and the use of compensatory strategies in attention-demanding activities of daily living, performing independent work with attention-demanding tasks at individual level and group activities
Study NCT01523925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dCIT
Description: This dCIT group focuses on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected upper extremity in functional tasks 1.5 hours/weekday, for 4 weeks. The level of challenge will be adapted based on patient ability and improvement during training. Patients will be encouraged to initiate the designed therapeutic functional activities.
Study NCT01523925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAT
Description: The BAT group concentrates on the simultaneous movements of both the affected and unaffected upper extremity on robot for 1.5 hours/day, 5 days/week for 4 weeks.
Study NCT01523925 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention group
Description: The conventional intervention group is designed to control for the duration and intensity of patient-therapist interactions and therapeutic activities (1.5 hours/day, 5 days/week, for 4 weeks). Therapy in the control intervention group will involve training for coordination, balance, and movements of the affected upper extremity, as well as compensatory practice on functional tasks with the unaffected upper extremity or both upper extremities.
Study NCT01523925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Study NCT03748407 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dosages of Thyroid parameters
Description: Dosages of the following parameters: TSH, FT4 FT3, TGAb (Tyroglobulin antibody) , TPO Ab (ThyroPeroxydase Antibody)
Study NCT03422588 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic right colectomy
Description: Laparoscopic right colectomy for colorectal cancer with a standard vascular dissection, performing the anastomosis with a side-to-side mechanical anastomosis fashioned intracorporeally versus extra corporeally
Study NCT03422588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic right colectomy
Description: Laparoscopic right colectomy for colorectal cancer with a standard vascular dissection, performing the anastomosis with a side-to-side mechanical anastomosis fashioned intracorporeally versus extra corporeally
Study NCT00414687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ventavis (Iloprost, BAYQ6256)
Study NCT03170154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clareon aspheric hydrophobic acrylic monofocal IOL
Description: Ultraviolet-absorbing and blue light-filtering IOL composed of high refractive-index foldable and flexible acrylic material. IOLs are implantable medical devices intended for long term use over the lifetime of the cataract subject.
Study NCT00905112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Receives manual therapy, stabilization exercise and patient education
Study NCT00905112 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard OB Care
Description: Receive standard obstetrical care
Study NCT00810394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Patients will be registered and started on the standard recommended dose-schedule for sorafenib (400 mg tablet by mouth twice a day continuously). Dose reductions will be instituted in the event of grade 3 or higher hematologic or non-hematologic toxicity or for any toxicity that is considered by the patient or physician as intolerable.
Study NCT01052922 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 sample g-SENSA
Description: Participants will be mailed to a 3 sample g-SENSA FOBT kit to complete at home and mail back to the lab for screening.
Study NCT01052922 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2 sample InSure
Description: Participants will be mailed to a 2 sample InSure FOBT kit to complete at home and mail back to the lab for screening.
Study NCT01052922 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1 sample OC-Micron
Description: Participants will be mailed to a 1 sample OC-MICRON FOBT kit to complete at home and mail back to the lab for screening.
Study NCT04452760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Physical exercise intervention
Study NCT04452760 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Testing sessions
Description: Testing sessions
Study NCT04452760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testing sessions
Description: Testing sessions
Study NCT02146326 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing (MI)
Description: MI is a common counseling technique. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to MI. Each session occurred approximately one month apart.
Study NCT02146326 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Burnout Reduction: Enhanced Awareness, Tools, Handouts, and Education (BREATHE)
Description: BREATHE is a program developed to attempt to improve or prevent the symptoms of burnout. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to BREATHE. Each session occurred approximately one month apart.
Study NCT03375528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DES implantation
Description: Coronary artery intervention using Drug eluting stent and Intravascular Ultrasound is performed.
Study NCT01613560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AI adjuvant therapy
Description: preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
Study NCT01613560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AI+chemotherapy adjuvant therapy
Description: preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years after adjuvant chemotherapy
Study NCT02656823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANKYLOS C/X implant A 6.6
Description: Treatment with six (6) 6.6 mm implants and a bridge to restore chewing function of an edentulous maxilla.
Study NCT02970877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal filtrate from 150 g stool from healthy lean donors
Description: 150 g stool from healthy lean donors will be diluted in 0.9% normal saline to a total volume of 450 mL. Preparation from frozen stool.
Study NCT02970877 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fecal filtrate from 150 g of the recipient's own stool
Description: 150 g stool from the recipient will be diluted in 0.9% normal saline to a total volume of 450 mL. Preparation from frozen stool.
Study NCT01104116 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]-FDG PET/CT imaging
Description: Drug: F-18 Fluoro-2-Deoxyglucose (F-18 FDG)
Study NCT00425802 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: filgrastim
Study NCT00425802 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: graft-versus-tumor induction therapy
Study NCT01350310 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramyocardial injection
Description: Electromechanical mapping will be used to identify viable myocardium (unipolar voltage >6.9 mV) and intramyocardial injections in the target areas will be performed with NOGA catheter (25 injections of 0.3 cc).
Study NCT01350310 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracoronary injection
Description: Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment. Microcatheter will be placed in the mid segment of the coronary artery supplying the segments of reduced tracer accumulation and repeated intracoronary injections of stem cell solution will be performed.
Study NCT01350310 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intramyocardial injection
Description: Procedure/Surgery: Intramyocardial injection Electromechanical mapping will be used to identify viable myocardium (unipolar voltage >6.9 mV) and intramyocardial injections in the target areas will be performed with NOGA catheter (25 injections of 0.3 cc).